Nuclear IRF-1 expression as a mechanism to assess “Capability” to express PD-L1 and response to PD-1 therapy in metastatic melanomaJames W. Smithy, David L. Rimm|Journal for ImmunoTherapy of Cancer|2017Cited by 43